Erinn B. Broshko, M.A., LL.B., M.B.A
Chief Executive Officer and Director

Erinn B. Broshko has been MBI's Chief Executive Officer since May 2006. Prior to joining MBI, Mr. Broshko was a corporate and securities lawyer with the Vancouver law firm of Farris, Vaughan, Wills & Murphy LLP. Mr. Broshko’s legal practice was focussed primarily on biotechnology companies and he represented clients in corporate transactions totalling in excess of $2.2 billion.

Mr. Broshko holds a B.A. (hons) and M.A. from the University of Saskatchewan, an LL.B. from Dalhousie Law School and an M.B.A. from the University of British Columbia.

Scott Davis, C.G.A.
Chief Financial Officer

Scott Davis has been MBI's Chief Financial Officer since December 2010.  Mr. Davis is a partner of Cross Davis & Company LLP Certified General Accountants, a firm focused on providing accounting and management contract services for publicly-listed companies.

Mr. Davis is a Certified General Accountant.

Heiner Dreismann, Ph.D.

Heiner Dreismann, Ph.D., has been a director of MBI and the chair MBI’s Strategy Committee since May 2008.  Dr. Dreismann is the former Chief Executive Officer of Roche Molecular Diagnostics (Roche), a division of F. Hoffmann-La Roche Ltd.

Roche pioneered the clinical implementation of molecular diagnostics. While at Roche, Dr. Dreismann led the introduction in Europe of the company’s PCR (polymerase chain reaction) and, now industry-standard, real-time PCR-based tests.  PCR is a Nobel-prize winning technology which has been recognized as one of the most important scientific developments of our generation.  PCR allows scientists to copy a single segment of DNA billions of times, making it possible to take a specimen, copy its genetic sequence, and, within hours, generate a test sample sufficient to perform a detailed analysis of a specific genetic question.

Under Dr. Dreismann’s leadership as Chief Executive Officer, Roche evolved into one of the world’s leading molecular diagnostics companies with annual sales to over US $1 billion and the significant expansion of their portfolio of diagnostic tests and hardware. Prior to his appointment as Chief Executive Officer, Dr. Dreismann held other senior positions within Roche in the areas of Global Business Development, Business Unit Manager for PCR and Microbiology, as well as R&D positions in microbiology and infectious diseases and in manufacturing.

Dr. Dreismann holds a Masters Degree in Biology and a Ph.D. in Microbiology/Molecular Biology from Westfaelische Wilhelms University in Muenster, Germany.

Dennis L. Grimaud

Dennis L. Grimaud has been a director of MBI since February 2008.  Mr. Grimaud has over 30 years of experience in the health care industry and over 18 years of experience in biotechnology and molecular diagnostics as an entrepreneur, senior executive and consultant.  Mr. Grimaud is currently the Chief Executive Officer of Theragnostix Reference Laboratories Inc., an innovative clinical laboratory providing diagnostic services for infectious disease.

From 2004 to 2006, Mr. Grimaud was the Chief Executive Officer of Genaco Biomedical Products, Inc., a molecular diagnostics company with proprietary multiplexing technology for infectious disease and cancer diagnostics.  In 2006, Mr. Grimaud led the sale of Genaco to global molecular diagnostics leader Qiagen (Nasdaq: QGEN). 

Kevin K. Rooney, Esq.

Kevin K. Rooney has been a director of MBI since June 2009.  Mr. Rooney is a partner in the corporate practice group of Sheppard Mullin Richter & Hampton LLP in the firm's Palo Alto, California office. Prior to that, Mr. Rooney was a co-founding partner of Hayden Bergman Rooney, Professional Corporation and a corporate and securities attorney at Wilson Sonsini Goodrich & Rosati, Professional Corporation, in Palo Alto, California, and Davies Ward Phillips & Vineberg LLP in Toronto. 

Mr. Rooney is an Adjunct Professor at the University of San Francisco School of Law teaching Corporate Transactions and an Adjunct Professor at the University of California Berkeley HAAS School of Business co-teaching Business Law (MBA).  Mr. Rooney is also a member of the TSX Venture Exchange Toronto Local Advisory Board, the Law Society of Upper Canada and The State Bar of California.

Mr. Rooney holds a B.A.Sc. (Honours Co-op) in Mechanical Engineering from the University of Waterloo and an LL.B. from Dalhousie Law School.